Chris Takimoto (Chief Medical Officer of Forty Seven) comments on the benefits for TAP partners.
 

Please join The Leukemia & Lymphoma Society's (LLS) Therapy Acceleration Program® (TAP) leadership for a one hour virtual discussion panel with past and current TAP portfolio partners.

Agenda:

• Introduction to the LLS TAP program
• Moderated discussion with TAP Company representatives from:
  • argenx
  • BioTheryX
  • Constellation Pharmaceuticals
  • Kura Oncology
  • Kymera Therapeutics
  • X4 Pharmaceuticals
• Q&A focused on the benefits TAP can provide to Portfolio Partners

Friday, Dec. 4, 2020

12 noon EST/9 am PST
via Zoom